Baudax Bio Inc (BXRXQ)

OTCMKTS: BXRXQ · Delayed Price · USD
0.0159
0.00 (0.00%)
Apr 11, 2024, 12:00 AM EDT - Market open
Market Cap 127.10K
Revenue (ttm) 310,000
Net Income (ttm) -7.16M
Shares Out 7.99M
EPS (ttm) 83.80
PE Ratio 0.00
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,438
Open n/a
Previous Close 0.0159
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About BXRXQ

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB revers... [Read more]

Industry Biotechnology
Sector Healthcare
Employees 9
Stock Exchange OTCMKTS
Ticker Symbol BXRXQ
Full Company Profile

Financial Performance

In 2022, Baudax Bio's revenue was $1.27 million, an increase of 17.50% compared to the previous year's $1.08 million. Losses were -$58.80 million, 197.4% more than in 2021.

Financial Statements

News

Baudax Bio Announces Corporate Update

Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition

6 months ago - GlobeNewsWire

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utiliz...

7 months ago - GlobeNewsWire

Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utiliz...

7 months ago - GlobeNewsWire

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizi...

8 months ago - GlobeNewsWire

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human...

8 months ago - GlobeNewsWire

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modes...

8 months ago - GlobeNewsWire

Baudax Bio shares jump on acquisition of TeraImmune

Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune...

10 months ago - Market Watch

Baudax Bio Acquires TeraImmune, Inc.

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax

10 months ago - GlobeNewsWire

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000 Secondary Efficacy Analyses, Including of Neuromuscular...

11 months ago - GlobeNewsWire

Baudax Bio Announces Date of Reconvened Annual Meeting

MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently an...

11 months ago - GlobeNewsWire

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio...

1 year ago - GlobeNewsWire

Baudax Bio to Present at the Sidoti Virtual Investor Conference

MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announce...

1 year ago - GlobeNewsWire

Baudax Bio Announces Closing of $4 Million Public Offering

MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related setting...

1 year ago - GlobeNewsWire

Baudax Bio Announces Pricing of $4 Million Public Offering

MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related setti...

1 year ago - GlobeNewsWire

Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial

MALVERN, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announ...

1 year ago - GlobeNewsWire

Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update

Company Focuses on Development of Neuromuscular Blocking Agents

1 year ago - GlobeNewsWire

Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000

MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful...

1 year ago - GlobeNewsWire

Baudax's stock rallies after announcing start to Phase 2 clinical trial

Shares of Baudax Bio Inc. BXRX, +20.77% soared 62.6% in premarket trading on Friday, the day after the company said it started a Phase 2 clinical trial evaluating an experimental treatment for neuromu...

1 year ago - Market Watch

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation...

1 year ago - GlobeNewsWire

Baudax Bio Announces Closing of $5 Million Public Offering

MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settin...

1 year ago - GlobeNewsWire

Baudax Bio Announces Pricing of $5 Million Public Offering

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today annou...

1 year ago - GlobeNewsWire

Baudax Bio Announces 1-for-40 Reverse Stock Split

MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Compa...

1 year ago - GlobeNewsWire

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

BX 1000 Phase II Trial Underway

1 year ago - GlobeNewsWire

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

MALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for acute care settings, today...

1 year ago - GlobeNewsWire

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, th...

1 year ago - GlobeNewsWire